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Abstract – Acute kidney injury (AKI) is a 
common complication associated with 
cardiac surgery. Those patients who 
develop AKI have increased hospital costs, 
hospital LOS and odds of death. The current 
diagnostic criteria rely on serum creatinine 
measurements and urine output data. 
Serum creatinine is not renal specific. It is 
known that there are other factors that 
influence serum creatine concentrations 
other than renal injury. Serum creatinine 
levels are measured as concentrations 
which means large changes in fluid balance 
may alter the serum creatinine 
measurement. Urine output is not a reliable 
measurement of renal injury either. During 
surgery it is common to administer diuretics 
which influence urine output independent 
of renal damage. Researchers are 
investigating novel biomarkers that are 
renal specific and can monitor AKI risk in 
real time. Some researchers are focused on 
identifying chemical biomarkers to 
diagnose AKI more effectively. Preliminary 
studies have also shown that urine oxygen 
concentration may be a physiological 
biomarker that can be used to monitor AKI 
risk in real time. Urine oxygen 
concentration may reflect tissue oxygen 
concentration in the medullary region of the 
kidney. The aim of this study was to 
investigate the relationship between urine 
biomarker concentrations, urine oxygen 
concentration and AKI diagnosis. The 
results from this study suggest that is 
possible to monitor oxygen concentration 
non-invasively and it could potentially be 
used to monitor AKI risk in real time.  
 
INTRODUCTION AND BACKGROUND 
 
Acute kidney injury (AKI) occurs in 
approximately 30% off all patients who 
undergo cardiac surgery.1 AKI is described by 
an acute decrease in renal function and is 
associated with decreased urine output and 
excess metabolites in the urine. One study 
found that mild to moderate AKI increased 
hospital length of stay (LOS), hospital 
associated costs and risk of death.2 Severe 
AKI, which requires renal replacement 
therapy (RRT), is associated with mortality 
rates as high as 50-90% and an 8-fold 
increase in the risk of death.3,4 Based on 
these data it is important to accurately 
diagnose AKI and further investigate 
therapies or treatments to protect patients 
from developing this syndrome.  
The definition of AKI has changed over time 
as new standards and criteria have been 
developed. The Acute Dialysis Quality 
Initiative (ADQI) group was the first group to 
develop a uniform diagnostic criterion, 
which became known as the RIFLE criteria. 
This standard uses a three tiered severity 
system that is based on the subjects 
glomerular filtration rate (GFR) or urine 
output.5 In 2007 the Acute Kidney Injury 
Network (AKIN) modified the RIFLE criteria 
with the hope of creating a uniform standard 
with higher sensitivity for detecting AKI. This 
definition of AKI is based on an increase in 
serum creatinine concentration or 
decreased urine output.6 A study from 
Engleberger et. al found that significantly 
more patients were diagnosed with AKI 
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when using the AKIN criteria compared to 
the RIFLE criteria.7 The most recent standard 
has been set forth by Kidney Disease 
Improving Global Outcomes (KDIGO) with 
the goal of creating a universal standard that 
could be uniformly applied to future 
research studies. This new standard is based 
on the previous RIFLE and AKIN criteria and 
uses serum creatinine concentrations or 
urine output data to diagnose patients with 
AKI.8 While increased serum creatinine 
concentrations and decreased urine output 
have been associated with impaired renal 
function, these markers are not perfect 
indicators of renal injury because they are 
influenced by factors other than kidney 
function.  
One study found that the half-life of creatine 
dramatically increases when there is a 5 % 
reduction in kidney function. This means 
that serum creatinine levels may not rise 
until several days after the initial renal 
injury. This does not help prevent or mitigate 
AKI, and shows that serum creatinine 
concentrations can only be used as a 
diagnostic tool.9 Because serum creatinine is 
measured as a concentration it is affected by 
changes in  volume. This means that patients 
who are given large amounts of fluid will 
have a lower serum creatinine 
concentration, independent of whether they 
experienced renal injury. It is also known 
that serum creatinine concentrations are 
affected by certain drugs that alter the 
concentration independent of renal injury or 
damage.10   Another concern with using 
serum creatinine as a measure of renal injury 
is that the definitions for AKI require a 
baseline measurement. If there is not a 
baseline measurement it is often estimated 
through various methods which require 
assumptions about the patient’s health and 
prior renal function. 
The validity of urine output as a marker for 
renal injury has also recently been 
questioned. Some researchers argue that 
the KDIGO urine output AKI definition has 
not been validated, and that the definition is 
too liberal. One study showed that those 
patients who were under a threshold of 0.3 
ml/kg/hr for 6 hours or longer had a higher 
risk of death and need for dialysis.11 The 
current criteria uses 0.5 ml/kg/hr as a 
threshold.  It is also important to consider 
that urine output is affected by 
administration of diuretics which are 
commonly given during surgery. For these 
reasons it is important to identify other 
physiological biomarkers that are renal 
specific, could be used to identify renal 
injury and monitor AKI risk in real time.  
Researchers have studied the role of 
neutrophil gelatinase-associated lipocalin 
(NGAL) as a potential biomarker for 
diagnosing AKI. It has been reported that 
following renal injury there is an increase in 
uptake of NGAL, which gives researchers 
hope that it can be used in place of the 
conventional biomarkers currently used.12 
Other studies have identified kidney injury 
mocule-1 and interleukin-18 as biomarkers 
that could potentially be used to detect 
AKI.13 Studies have also been done to 
determine if urine oxygen concentration can 
be used a physical biomarker to detect AKI.  
Several studies have shown that tissue 
hypoxia is a final common pathway for 
multiple forms of AKI.14 Even though the 
kidneys receive 20-25% of the cardiac output 
and only extract 10-20% of the oxygen 
delivered to them they are susceptible to 
hypoxia. This is because the medullary 
region of the kidney accounts for 
approximately 80% of the oxygen extraction 
associated with the kidney and due to 
complex oxygen conservation and delivery 
mechanisms receives oxygen poor blood.15 It 
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would be ideal to directly measure the tissue 
oxygen concentration in the medullary 
region of the kidney, however this is not 
currently feasible in a clinical setting.  
To identify a physiological biomarker to 
better identify renal injury researchers have 
investigated the relationship between urine 
oxygen concentration and tissue oxygen 
concentration in the medulla. The collection 
of blood vessels known as the vasa recta run 
parallel and lie near the urinary collecting 
ducts in the medullary region. Pannabecker, 
Datnzler and Thomas et al. showed that due 
to this spatial relationship the urine oxygen 
concentration approximated the tissue 
oxygen concentration in the medullary 
region of the kidney. In addition, Evans et al. 
has demonstrated that it is feasible to 
measure urinary oxygen concentration in 
the bladder and that those who later 
develop AKI spend more time below a 
designated urinary oxygen concentration 
threshold than those who do not develop 
AKI.16 Other studies have shown that urinary 
oxygen concentration may be a viable 
surrogate measurement for monitoring 
renal hypoxia.17–19 
The goal of this research was to investigate 
potential biomarkers that could be used to 
monitor AKI risk and diagnose AKI 
intraoperatively. A novel device that non-
invasively measured urinary oxygen 
concentration and urine flow rate was 
developed. Identifying novel biomarkers 
that could be used intraoperatively could 
help mitigate or prevent the development of 
AKI. It would also help researchers further 
study different therapies and interventions 
to mitigate or prevent surgery associated 
AKI. Preventing surgery associated AKI 
would improve surgical outcomes, save 
people’s lives, and reduce costs associated 




After IRB approval and informed consent 38 
patients scheduled for cardiothoracic 
surgery were enrolled at University of Utah 
Health Sciences. PuO2, temperature, and 
urinary flow sensors were installed between 
the urinary catheter and the tubing going to 
the urinary collection bag. All sensors were 
sampled at 1 Hz. The device was removed 24 
Figure 1 - An image of the device that was used to measure urine oxygen concentration and urine flow rate. The device was 
placed between the end of the urinary catheter and the tubing that goes to the urine collection bag. 
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hours after the end of cardiopulmonary 
bypass. After removal, each device was 
calibrated according to a calibration 
protocol.  
The concentration of five urinary biomarkers 
(NGAL, KIM-1, IL-18, MCP-1, YKL-40) were 
measured at baseline (shortly after 
placement of urinary catheter) and 12-hours 
post cardiopulmonary bypass. For each 
patient, the percent change from baseline 
was calculated for each biomarker. A 
percent change in the upper tertile for any 
biomarker was defined as "subclinical AKI."  
"Clinical AKI" was defined as meeting the 
KIDGO criteria for AKI based on serum 
creatinine measurements.4 Patients with 
subclinical or clinical AKI, were in the AKI 
group, patients with neither subclinical nor 
clinical AKI were in the "No AKI" group.  
An average calibration curve was calculated. 
The calibration curve was applied to the raw 
oxygen data to obtain oxygen concentration 
measurements. The oxygen concentration 
and urine flow signals were combined to 
calculate the oxygen mass flow rate. The 
average oxygen mass flow rate, average 
oxygen concentration, and average urine 
flow rate during cardiopulmonary bypass 
were calculated for each patient in the “No 
AKI” and “AKI” groups. When comparing the 
means of two groups a two-tailed t-test was 
used. Eleven patients were excluded from 
the analysis because they were diagnosed 
with clinical AKI before the procedure, they 
required a non-latex urinary catheter, or 
their baseline measurement for any of the 




The average oxygen mass flow rate (mean ± 
SD) for the AKI group (n=12) was 337.62 ± 
238.57 g/hr. For the No AKI group (n=14) the 
average rate was 669.18 ± 381.75 g/hr. 
Figure 2 - The comparison of the average mass flow rate 
for the AKI and No AKI group. The difference was 
statistically significant (P = 0.019) 
Figure 3 - The comparison of the average urine oxygen 
concentration for the AKI and No AKI groups. There was 
not a statistically significant difference between the 
groups. 
Figure 4 - The comparison of the average oxygen mass 
flow rate for the AKI, Subclinical AKI, and the Subclinical 
and Clinical AKI groups. Those who had both forms of AKI 
had the lowest average oxygen mass flow rate. 
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Patients diagnosed with AKI had a 
statistically significant lower average oxygen 
mass flow rate than those who were not 
diagnosed with AKI (p = 0.019, figure 2). 
There was not a statistically significant 
difference between the average oxygen 
concentration for the AKI and No AKI groups 
(figure 3).  
Subjects who had both clinical and 
subclinical AKI had a lower oxygen mass flow 
rate compared to the other groups. Those 
subjects with only subclinical AKI had a lower 
oxygen mass flow rate than those who did 
not have AKI (figure 4).  
      
DISCUSSION 
 
AKI is common complication associated with 
cardiac surgery. Those who develop AKI have 
increased risk of death and hospital LOS. 
Current diagnostic criteria are based on 
serum creatinine concentrations and urine 
output data. These measures are insufficient 
because they are not renal specific and can 
only be used for diagnostic purposes after 
the surgery is complete. Researchers are 
focused on identifying novel biomarkers to 
detect AKI intraoperatively. Many studies 
have shown that certain chemical 
biomarkers such as NGAL, KIM-1 and IL-18 
have potential to detect AKI much earlier 
than the current methods. Preliminary 
research also shows that measuring urine 
oxygen concentration in the bladder may be 
a viable alternative to monitoring renal 
hypoxia which is associated with increased 
risk of developing AKI. The purpose of this 
study was to investigate the relationship 
between several different biomarkers, urine 
oxygen tension outside the body and AKI 
diagnosis.  
This study showed the it is possible to 
measure urine oxygen concentration outside 
the body and that it could potentially be 
used to monitor renal hypoxia. However, 
based on the urine oxygen concentration 
data and previously published research 
there are other factors that confound the 
oxygen concentration measurement. As the 
urine travels through the ureter, into the 
bladder and then through the urinary 
catheter to our device outside the body 
oxygen may diffuse in or out of the urine. 
The quantity of oxygen that diffuses in or out 
of the urine is likely dependent on the urine 
flow rate. Future models may help account 
for the oxygen diffusion which currently 
confounds the signal.  
In addition, this study showed that there are 
biomarkers that are more sensitive than 
creatinine for detecting renal injury. 
Creatinine is not renal specific and therefore 
may not be specific enough to detect all 
cases of renal injury. Another advantage to 
using these biomarkers is that may detect 
AKI sooner than current methods.  
Limitations of this study include the 
population size and the definition of AKI. 
Clinical AKI was defined only using serum 
creatinine concentration and not urine 
output. It has been shown that urine output 
is associated with AKI diagnosis so future 
work should include urine output in the AKI 
diagnosis. Subclinical AKI was an arbitrary 
definition and further research is needed to 





In summary, the current methods for 
detecting AKI are not renal specific and 
cannot be used as a diagnostic tool in real 
time.  To prevent AKI, it is important to 
detect AKI risk in real time. Urine oxygen 
concentration and chemical biomarkers are 
two potential methods that could be used to 
monitor AKI risk. However, more research is 
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needed to validate preliminary results and 
refine the technology to obtain 
measurements that reflect medullary tissue 
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